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Background: Hepatoid carcinoma of the pancreas is extremely rare. This article tries to summarize the clinical
features and outcomes of pancreatic hepatoid carcinoma.
Methods: The data pool for analysis includes the case we encountered with hepatoid carcinoma of the pancreas
and the reported cases in the literature.
Results: Twenty-three cases of hepatoid carcinoma of the pancreas were analyzed. This tumor occurred more
frequently in male than in female patients (69.6 vs. 30.4 %). Tumor sizes range from 0.5 to 11.0 cm with median of
6.0 cm. The most common symptom was epigastric pain (36.4 %). When the tumor locates at pancreatic head,
nausea/vomiting (62.5 %) is more common, followed by jaundice and epigastric pain (50.0 %). For those at pancreatic
body-tail, 42.9 % of the patients presented no symptom. Alpha-fetoprotein (AFP) was abnormally elevated in 60 % of the
cases. Hepatoid carcinoma in the pancreas could be either pure form or mixed form with other malignancy (40.9 %),
with the most common coexisted pathology of malignant neuroendocrine tumor (22.7 %). Metastasis occurred in 36.4 %
of the cases at the diagnosis of this tumor, including liver metastasis in 31.8 % and lymph node metastasis in 21.1 %. The
overall 1-year survival rate was 71.1 % and 5-year 40.4 %, with a median of 13.0 months. Unresectability, hepatic, and
lymph node metastases are associated with negative impact on survival outcome.
Conclusions: Elevation of serum AFP may be a clue leading to the diagnosis of pancreatic hepatoid carcinoma. This
tumor could be mixed form with other malignancy. Surgical resection should be the treatment of choice whenever
possible.
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Hepatoid carcinoma is a primary extrahepatic neoplasm
resembling hepatocellular carcinoma in terms of morph-
ology and immunohistochemistry and often produces
alpha-fetoprotein (AFP) [1–8]. The first case reported by
Ishikura et al. in 1985 was described in the stomach [9],
while Hruban et al. reported the first case in the pan-
creas in 1987 [5, 10]. Subsequently, documentation of
this unique histopathologic feature has been made in other
extrahepatic sites including the esophagus, papilla of Vater,
colon, lung, gallbladder, adrenal gland, kidney, urinary
bladder, ovary, uterus, vagina, and testicle [1, 5–9, 11–23].
The most common location was stomach, followed by
ovary [1–5, 24]. However, hepatoid carcinoma of the* Correspondence: sewang0408@gmail.com
†Equal contributors
1Division of General Surgery, Department of Surgery, Taipei Veterans General
Hospital, National Yang Ming University, 10 F 201 Section 2 Shipai Road,
Taipei 112, Taiwan
Full list of author information is available at the end of the article
© 2015 Kuo et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.pancreas is distinctly rare, and the true incidence is still
unknown. In the pancreas, hepatoid carcinoma could be
pure form or mixed with other histological components
such as neuroendocrine tumor or pancreatic ductal adeno-
carcinoma. As to the pure hepatocellular features, they
have been designated variously as hepatoid carcinoma,
hepatoid adenocarcinoma, ectopic hepatocellular carcin-
oma, hepatoid variant of pancreatic cancer, primary hepa-
tocellular carcinoma of the pancreas, or pancreatic tumor
with hepatoid differentiation [11, 12, 23, 25–31]. Like most
pancreatic neoplasms, it is often clinically silent until
symptoms of obstruction, pain, or bleeding occur. Hepa-
toid carcinoma of the pancreas has been claimed to have
an unfavorable survival outcome because the majority have
already metastasized at diagnosis, most frequently to the
liver and lymph nodes [5, 9, 11, 19, 22]. Their aggressive-
ness could derive from a propensity to proliferate in
lymphatic and venous vessels mimicking the behavior of
hepatocellular carcinoma in the liver [3, 32]. With its rarity
and limited experience from sporadic case reports in theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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carcinoma of the pancreas have not been clarified so far.
The purposes of this article are to present our clinical
experience with hepatoid carcinoma of the pancreas and
to analyze an expanded sample size by adding cases
from the literature to our pool of study cases. Thus, an
attempt is made to clarify the characteristics, clinical
presentations, managements, and survival outcomes of
this rare tumor.Methods
Brief descriptions for the case of hepatoid carcinoma of
the pancreas encountered at our institute were made. To
clarify the characteristics of hepatoid carcinoma of the
pancreas, individualized data of cases with hepatoid
carcinoma of the pancreas reported in the English litera-
ture were extracted and added to our database to expand
the study sample size for a more complete analysis. Two
methods were utilized to search for relevant cases in the
literature. First, to identify the relevant articles dealing
with hepatoid carcinoma of the pancreas in the English
literature, a computerized search was performed on the
PubMed electronic database, covering data from 1987 to
2014. The following keywords were used for the PubMed
search: hepatoid carcinoma of the pancreas, hepatoid
differentiation of the pancreas, ectopic liver cancer, and
rare pancreas neoplasm. Second, the reference lists of
PubMed-selected articles related to hepatoid carcinoma of
the pancreas were screened systematically for additional
studies of interest. A total of 20 related articles were se-
lected for the study [2–5, 7, 10–12, 23, 25–31, 33–36].
Cases without individualized data or duplicate cases re-
ported in literature were excluded from analysis. The data
pool from the related literature and our case were analyzed
to determine the characteristics of hepatoid carcinoma of
the pancreas including demographics, tumor size, tumor
markers, hepatitis markers, clinical presentations, histo-
pathology, treatments, and survival outcomes. These data
were also used to make comparisons between two groups:
one in pancreatic head and the other one in body-tail.
The statistical analysis was performed using Statistical
Product and Service Solutions (SPSS) version 21.0 soft-
ware (SPSS Inc., IBM, Armonk, NY, USA). All continu-
ous data were calculated using median and mean ±
standard deviation (SD) and frequencies, as appropriate
to the type of data. The mean values of the continuous
variables were compared with a two-tailed Student t test.
Non-parametric statistical tests were used if the variables
did not follow normal distribution. Categorical variables
were presented as numbers and percentages. Categorical
variables were compared using Pearson’s χ2 test or Fish-
er’s exact test contingency tables. The Kaplan-Meier
method was used for the calculation of median survivaland survival analysis. For all analyses, a P value less than
0.050 was considered statistically significant.
Results
A total of 23 cases of hepatoid carcinoma of the pan-
creas were collected for this study, including 22 cases
from case reports in literature and 1 from our institute.
Our case was a 67-year-old male who presented with no
symptom but an incidental finding of pancreatic tail
mass during survey examinations for recent hyperten-
sion. The serum amylase, lipase, and tumor markers
including AFP, carbohydrate antigen 19-9 (CA 19-9),
and carcinoembryonic antigen (CEA) were all normal.
Serum markers for hepatitis B and C were also negative.
The image studies showed a 2 × 2 cm heterogeneous
hypodense nodule at pancreatic tail in pre-contrast
computed tomography (CT) scan. After contrast
administration, a well-enhanced tumor with a rim
encapsulation was identified (Fig. 1). The nodule showed
signal drop (fat) on T1 opposed phase in magnetic reson-
ance imaging (MRI) study, probably due to fatty metamor-
phosis; however, the lesion was isosignal (no water) on T2
weighted MRI images. The patient underwent robotic dis-
tal pancreatectomy with spleen-preservation by Warshaw
technique and recovered uneventfully. The cut section of
the mass showed a well-circumscribed, yellow to brown,
soft, 2 × 2 cm tumor with partial encapsulation (Fig. 2a),
resembling the gross features of hepatoma in the liver.
Microscopic examination revealed the tumor cells were
polygonal with abundant eosinophilic granular cytoplasm
and presented with trabecular and acinar growth pattern
(Fig. 2b), in which bile formation was also noted (Fig. 2c).
The tumor cells were also positive for hepatocyte antigen
in histochemical stain (Fig. 2d). He had been followed up
for 6 months postoperatively without any signs of
recurrence.
Table 1 lists the demographics and clinical presenta-
tions of the 23 cases of hepatoid carcinoma of the pan-
creas. More than half of the cases (60.9 %) were located
in pancreatic body-tail. Two cases were diffuse or multi-
focal, but more prominent in pancreatic head, so they
were classified into pancreatic head group for statistical
analysis. This tumor occurred more frequently in male
patients than in female, 69.6 vs. 30.4 % for total patients,
77.8 vs. 2.2 % for pancreatic head group, and 64.3 vs.
35.7 % for pancreatic body-tail group. The median age
was 56 years old, ranging from 21 to 80 years old for
overall patients. The median tumor size was 6.0 cm,
ranging from 0.5 to 11.0 cm, and there was no signifi-
cant difference of tumor size between pancreatic head
and body-tail groups. Hepatitis B and C were all negative
in the reported cases. AFP was abnormally elevated in
60 % of total group, 71.4 % of pancreatic head group,
and 50 % of pancreatic body-tail group. Both CA 19-9
Fig. 1 a A heterogeneous hypodense nodule (white arrow) is depicted at pancreatic tail in pre-contrast CT; b After contrast administration, a
well-enhanced tumor with pseudocapsule (white arrow) is identified; c The nodule shows signal drop (fat) on T1 opposed phase MRI image,
probably due to fatty metamorphosis (white arrow); d However, the lesion is isosignal (no water) on T2 weighted MRI image (white arrow)
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patients. For overall patients, the most common symp-
tom was epigastric pain (36.4 %), followed by nausea/
vomiting (31.8 %). For pancreatic head group, the most
common symptom was nausea/vomiting (62.5 %),
followed by epigastric pain and jaundice (50.0 %). ForFig. 2 a A well-circumscribed with partial encapsulation (white arrow), yello
tumor cells, which are polygonal and have abundant eosinophilic granular
which bile formation (yellow arrow) is also present; d Positive staining (browpancreatic body-tail group, 42.9 % presented no symp-
tom and 28.6 % epigastric pain.
Hepatoid carcinoma in the pancreas could be either
pure (59.1 %) form or mixed (40.9 %) with other histo-
logical findings (Table 2). The most common coexisted
pathology was malignant neuroendocrine tumor (22.7 %)w-brown, soft 2 × 2 cm tumor in pancreatic tail; b Thick trabeculae of
cytoplasm; c Trabecular and acinar growth pattern of the tumor in
n in color on the right side) for hepatocyte antigen
Table 1 Demographics and clinical presentations of hepatoid carcinoma of the pancreas
Total Pancreatic head Pancreatic body-tail P value
Sex n = 23 n = 9 n = 14 0.418
Male 16 (69.6 %) 7 (77.8 %) 9 (64.3 %)
Female 7 (30.4 %) 2 (22.2 %) 5 (35.7 %)
Age (year) n = 23 n = 9 n = 14 0.156
Median (range) 56 (21–80) 49 (21–80) 58 (32–79)
Mean ± SD 53.8 ± 14.9 48.2 ± 17.5 57.4 ± 12.3
Size (cm) n = 20 n = 8 n = 12 0.907
Median (range) 6.0 (0.5–11.0) 6.3 (0.5–9.0) 6.0 (1.0–11.0)
Mean ± SD 5.5 ± 2.7 5.6 ± 2.8 5.5 ± 2.8
Hepatitis B (+), n = 8 0 0 0 N/A
Hepatitis C (+), n = 8 0 0 0 N/A
Elevation of tumor markers
AFP, n = 15 9 (60.0 %) 5 (71.4 %) 4 (50.0 %) 0.378
CA 19-9, n = 11 2 (18.2 %) 1 (25.0 %) 1 (14.3 %) 0.618
CEA, n = 11 2 (18.2 %) 1 (25.0 %) 1 (14.3 %) 0.618
Symptom n = 22 n = 9 n = 14
No symptom 7 (31.8 %) 1 (12.5 %) 6 (42.9 %) 0.161
Epigastric pain 8 (36.4 %) 4 (50.0 %) 4 (28.6 %) 0.291
Nausea/vomiting 7 (31.8 %) 5 (62.5 %) 2 (14.3 %) 0.032
Diabetes mellitus 5 (22.7 %) 1 (12.5 %) 4 (28.6 %) 0.308
Jaundice 4 (18.2 %) 4 (50.0 %) 0 0.010
Back pain 4 (18.2 %) 2 (25.0 %) 2 (14.3 %) 0.465
Body weight loss 3 (13.6 %) 1 (12.5 %) 2 (14.3 %) 0.797
Hypoglycemia 1 (4.5 %) 0 1 (7.1 %) 0.636
Skin rash 1 (4.5 %) 0 1 (7.1 %) 0.636
Subcutaneous fat necrosis 1 (4.5 %) 0 1 (7.1 %) 0.636
Gastrointestinal bleeding 1 (4.5 %) 0 1 (7.1 %) 0.636
Night sweating 1 (4.5 %) 0 1 (7.1 %) 0.636
Others 2 (15.4 %) 0 2 (14.3 %) 0.462
N/A not available, AFP alpha-fetoprotein, CA 19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen
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docrine carcinoma, one malignant glucagonoma (4.5 %),
and one malignant insulinoma (4.5 %), followed by ductal
adenocarcinoma (9.1 %). Overall, metastasis occurred in
36.4 % of the cases at the diagnosis of this tumor, includ-
ing liver metastasis in 31.8 % and lymph node metastasis
in 21.1 %. Most (85.0 %) of the patients underwent surgi-
cal resection.
The overall 1-year and 5-year survival rates were 71.1
and 40.4 % respectively, with a median of 13.0 months
and a mean of 18.1 ± 21.8 months (Table 3). Metastasis,
either liver or lymph node metastasis, has negative im-
pact in survival outcome. Prognosis in tumor resection
group was significantly better than non-resection group.
Long-term survival is possible only in the resection
group with 53.5 % 1-year and 53.5 % 5-year survival, andall the patients without resection died within 1 year after
diagnosis. Tumor location (head vs. body-tail) and histo-
pathology (pure vs. mixed form) did not play a signifi-
cant role in predicting the survival outcome.
Discussion
Hepatoid means “liver-like”. Therefore, hepatoid carcin-
oma often refers to a tumor-like primary hepatocellular
carcinoma in the liver but extrahepatic location. These
tumor cells have characteristic features similar to those
of hepatocellular carcinoma. Microscopically, hepatoid
carcinoma is composed of cords of polygonal cells with
abundant, eosinophilic cytoplasm and centrally located
nuclei in the sheet-like or trabecular portions, occasion-
ally featuring bile production and/or bile canaliculi for-
mation, and together with elevated serum levels of AFP
Table 2 Pathology and treatment for hepatoid carcinoma of the pancreas
Total Pancreatic head Pancreatic body-tail P value
Histopathology n = 22 n = 9 n = 13 0.205
Pure hepatoid carcinoma 13 (59.1 %) 4 (44.4 %) 9 (69.2 %)
Mixed with other pathology 9 (40.9 %) 5 (55.6 %) 4 (30.8 %)
Nonfunctioning NEC 3 (13.6 %) 3 (33.3 %) 0
Ductal adenocarcinoma 2 (9.1 %) 1 (11.1 %) 1 (7.7 %)
Malignant glucagonoma 1 (4.5 %) 0 1 (7.7 %)
Malignant insulinoma 1 (4.5 %) 0 1 (7.7 %)
Nonfunctioning NET 1 (4.5 %) 1 (11.1 %) 0
Acinar cell carcinoma 1 (4.5 %) 0 1 (7.7 %)
Metastasis at diagnosis 8 (36.4 %) 2 (22.2 %) 6 (46.2 %) 0.246
Lymph node metastasis 4 (21.1 %) 1 (14.3 %) 3 (25.0 %) 0.525
Liver metastasis 7 (31.8 %) 2 (22.2 %) 5 (38.5 %) 0.372
Treatment n = 20 n = 8 n = 12 0.670
Surgery Pancreaticoduodenectomy 17 (85.0 %) 7 (87.5 %) 10 (83.3 %)
Distal pancreatectomy 5 (25.0 %) 5 (62.5 %) 0
Enucleation 9 (45.0 %) 0 9 (75.0 %)
Total pancreatectomy 1 (5.0 %) 1 (12.5 %) 0
Surgery + chemotherapy 2 (10.0 %) 1 (12.5 %) 1 (8.3 %)
Surgery + TAE 1 (5.0 %) 1 (12.5 %) 0
Surgery + chemotherapy + TAE 1 (5.0 %) 0 1 (8.3 %)
Surgery + radiotherapy + TAE 1 (5.0 %) 0 1 (8.3 %)
No treatment 1 (5.0 %) 0 1 (8.3 %)
Other 2 (10.0 %) 1 (12.5 %) 1 (8.3 %)
1 (5.0 %) 0 1 (8.3 %)
NEC neuroendocrine carcinoma, NET neuroendocrine tumor, TAE transarterial embolization
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Tumor cells may show one or a mixture of trabecular,
medullary, and glandular patterns, and varying degrees
of differentiation, ranging from well-differentiated with a
morphology typical of hepatocytes to less differentiated
and irregular forms [3].
The pathogenesis of hepatoid carcinoma of the pan-
creas is not completely understood. There are two theor-
ies to explain the histopathological features of this
unique tumor. One is “ectopic liver” theory from the
point of view of embryology. Since the pancreas and
liver cells are both derived from the foregut endoderm,
ectopic liver tissue probably exists in the pancreas. This
theory of common embryologic origin appears to be the
most widely accepted pathogenetic mechanism of the
extrahepatic hepatoid carcinoma. It is believed that acti-
vation of the process of liver-specific carcinogenesis
could also occur in the ectopic liver tissue in the pan-
creas [1, 2, 11, 30, 37]. The reported incidence of ectopic
liver tissue in different organs ranges between 0.24 and
0.47 % [37, 38]. Ectopic liver tissue is also reported in
several sites, such as the stomach, gallbladder, hepaticligaments, omentum, retroperitoneum, and thorax where
hepatoid carcinoma has been reported [1, 11, 30, 37].
These evidences suggest that hepatoid carcinoma could
originate from ectopic liver tissue in the pancreas. The
other histogenic mechanism is “pancreas-to-liver trans-
differentiation” theory, which might be related to multi-
potent/stem cells in the pancreas. Hepatocyte function
following the transdifferentiation has been demonstrated
in the animal studies as the pancreas of adult mice con-
tains hepatocyte progenitor cells capable of significant
therapeutic liver reconstruction [39, 40]. It is claimed
that pancreatic multipotent/stem cells normally suppress
hepatocytic differentiation genes, which could be acti-
vated during carcinogenesis or under particular un-
known environmental conditions [1, 28, 33, 35, 36].
Hepatocyte transdifferentiation from native pancreatic
ductal, acinar, or intermediate cells has been docu-
mented in animal models following exposure to carcino-
gens and copper depletion [4, 23]. This theory might
provide an explanation for and could be supported by
the pathological findings in mixed hepatoid tumors in
the pancreas [4]. So far, no association of hepatitis B and
Table 3 Survival and prognosis for hepatoid carcinoma of the pancreas
Case n Median (range) Mean ± SD 1-year survival 5-year survival P value
Total 22 13.0 (2.0–101.0) 18.1 ± 21.8 71.1 % 40.4 %
Location 0.780
Pancreatic head 9 8.0 (3.0–48.0) 14.3 ± 14.8 77.8 % 29.2 %
Pancreatic body-tail 13 14.0 (2.0–101.0) 20.7 ± 25.9 51.3 % 51.3 %
Histopathology 0.763
Pure hepatoid carcinoma 13 12.0 (2.0–48.0) 15.5 ± 13.3 56.1 % 56.1 %
Mixed hepatoid carcinoma 8 11.0 (2.8–101.0) 22.7 ± 32.9 75.0 % 25.0 %
Metastasis 0.001
No 13 15.0 (4.0–48.0) 18.5 ± 12.3 88.9 % 59.3 %
Yes 8 4.5 (2.0–101.0) 18.9 ± 33.8 25.0 % 12.5 %
Lymph node metastasis <0.001
No 15 15.0 (4.0–101.0) 23.7 ± 24.5 83.3 % 62.5 %
Yes 4 4.5 (2.0–12.0) 5.8 ± 4.5 0 0
Liver metastasis 0.003
No 15 14.0 (4.0–48.0) 17.2 ± 11.9 80.8 % 53.9 %
Yes 7 3.0 (2.0–101.0) 20.0 ± 36.4 28.6 % 14.3 %
Resection of tumor <0.001
Yes 17 15.0 (2.0–101.0) 21.8 ± 23.6 53.5 % 53.5 %
No 3 6.0 (3.0–12.0) 7.0 ± 4.6 0 0
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this study. It implies that viral hepatitis might not play a
significant role in the pathogenesis of this extrahepatic
hepatoid carcinoma.
The median age of reported patients was 56 years
(range 21–80), about 7 years less than the age of patients
with hepatocellular carcinoma and 15 years less than the
age of patients with pancreatic ductal adenocarcinoma.
Gender was predominant in male patients (69.6 %),
which was similar to that of hepatocellular carcinoma,
instead of pancreatic ductal adenocarcinoma [2, 10, 26].
More than half of the cases of this tumor (60.9 %) were
located in pancreatic body-tail by this study, whereas
approximately 75 % of all pancreatic carcinomas occur
within the head or neck of the pancreas, 15–20 % occur
in the body of the pancreas, and 5–10 % occur in the tail
[41]. Therefore, many cases, 31.8 % in this study, were
asymptomatic and incidentally discovered. Overall, the
most common presenting symptom was epigastric pain
(36.4 %), followed by gastrointestinal upset with nausea
and/or vomiting (31.8 %). However, when the pancreatic
hepatoid carcinoma was in pancreatic head, jaundice
was nevertheless a common clinical presentation (50 %),
similar to pancreatic head adenocarcinoma. Elevation of
serum AFP level was often present at time of diagnosis
[1, 8, 12, 14, 15, 18, 19, 23, 26, 31, 42, 43], as also shown
in 60 % of the cases of this study. On the contrary,
serum CA 19-9 and CEA were not a good diagnostictool for this tumor because these two tumor markers
were not usually elevated. Interestingly, this study
showed that many (40.9 %) of the pancreatic hepatoid
carcinomas could be mixed with other tumor compo-
nents such as nonfunctioning as well as functioning neu-
roendocrine tumors, pancreatic duct adenocarcinoma,
and even rare acinar cell carcinoma which might present
subcutaneous fat necrosis [5].
The main differential diagnosis of (primary) hepatoid
carcinoma of the pancreas would be secondary (metastatic)
hepatocellular carcinoma from the liver. Since these two
tumors share numerous clinicopathological features such
as morphology, immunohistochemistry, and elevated
serum AFP, differential diagnosis between the primary and
secondary could be very challenging [1, 3]. Clinically, the
incidence of hepatocellular carcinoma spreading to the
pancreas is low, only 2.7–5.6 %, and the metastasis is usu-
ally a late finding [1, 44]. Long-term follow-up is needed to
exclude the possibility that the pancreatic tumor represents
a metastasis from the liver [1]. If bile production cannot be
identified histologically, then the differential diagnosis
should also include other primary pancreatic tumors with
large eosinophilic tumor cells, such as intraductal oncocy-
tic papillary neoplasms, pancreatoblastoma, poorly differ-
entiated pancreatic adenocarcinoma, islet cell tumors, and
acinar cell carcinoma, but should be easily distinguished by
histological examinations for their own characteristics of
morphology and immunohistochemistry [1, 3–5, 28].
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approach is far from being standardized. Nevertheless,
85 % of reported cases underwent surgery. Radical surgi-
cal resection seems to be the best treatment for disease-
free survival [3–5, 11, 12, 23, 25, 27, 30, 33, 34, 36, 42].
It suggests that surgical resection be the treatment of
choice, whenever possible, and complete resection of the
tumor appears to be the best option. The roles of other
postoperative treatment modalities are still unclear [1–3].
A certain degree of response to chemotherapy with long-
term survival has been reported in locally unresectable,
metastatic or recurrent disease [23, 42]. Therefore, it
implies that aggressive treatment could be warranted even
in the case of locally advanced diseases and resection of
metastases might be considered as well [1, 23, 28, 42].
Survival outcomes of the pancreatic hepatoid carcin-
oma are variable in reported cases and appear unclear
due to its rarity and possible heterogeneity [1, 3, 26, 34].
Our study shows that overall 1-year survival rate is 71.1
% and 5-year 40.4 %, with a median of 13.0 months and
a mean of 18.1 ± 21.8 months. Neither tumor location
(head vs. body-tail) nor histopathology (pure vs. mixed
pancreatic hepatoid carcinoma) plays a role in the prog-
nosis. Presence of metastasis, either lymph node or liver,
would predict poor survival outcome. Long-term sur-
vival is possible only in the resection group, with 53.5
% 1-year and 5-year survival after resection. The
median survival (6.0 months) for the unresectable
group is similar to that for unresectable pancreatic
adenocarcinoma. However, the natural history and
prognosis of the disease could not be accurately pre-
dicted with limited data.Conclusions
Hepatoid carcinoma of the pancreas is an extremely rare
tumor. Elevation of serum AFP may be a clue leading to
the diagnosis of this tumor; however, preoperative diag-
nosis is still challenging since there is no characteristic
clinical features and, therefore, diagnosis is usually made
based on specific histological findings after resection. No
association of hepatitis B and C with pancreatic hepatoid
carcinoma has been reported so far. This tumor could
be mixed with other more common pancreatic tumors,
such as neuroendocrine tumors and even ductal adeno-
carcinoma. Surgical resection should be the treatment of
choice whenever possible since long-term survival is
possible only in the resection group. Presence of lymph
node or liver metastasis would predict poor survival
outcome.
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